Spots Global Cancer Trial Database for gastroesophageal junction adenocarcinoma
Every month we try and update this database with for gastroesophageal junction adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | NCT02389751 | Gastroesophagea... Malignant Neopl... Malignant Neopl... Stage IIA Esoph... Stage IIB Esoph... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | Carboplatin Ganetespib Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | NCT02514551 | Gastric Adenoca... Gastroesophagea... | Ramucirumab Paclitaxel | 18 Years - | Eli Lilly and Company | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | NCT04361708 | Pancreatic Aden... Gastroesophagea... Adenocarcinoma | Oxaliplatin Docetaxel Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | University of Chicago | |
| Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections | NCT02077673 | Gastroesophagea... Surgery | 18 Years - | Rigshospitalet, Denmark | ||
| Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | NCT06341647 | Breast Cancer Gastric Cancer Gastroesophagea... | AB-201 Cyclophosphamid... Fludarabine | 18 Years - | GC Cell Corporation | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | NCT05008783 | Gastric Adenoca... Gastroesophagea... | AK104 Placebo | 18 Years - 75 Years | Akeso | |
| Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | NCT05472857 | Gastric Cancer Pancreatic Canc... Advanced Ovaria... Gastroesophagea... | Claudin 18.2 CA... | 18 Years - 70 Years | Suzhou Immunofoco Biotechnology Co., Ltd | |
| A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | NCT02314117 | Metastatic Gast... Gastroesophagea... | Ramucirumab Capecitabine Cisplatin Placebo Fluorouracil | 18 Years - | Eli Lilly and Company | |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | NCT02443883 | Gastric Adenoca... Gastroesophagea... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) | NCT04447352 | Gastric Cancer Gastroesophagea... | 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel Cisplatin | 18 Years - 75 Years | Krankenhaus Nordwest | |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | NCT03802591 | Gastric Adenoca... Gastroesophagea... | CS1001 monoclon... CS1001 placebo Oxaliplatin Capecitabine | 18 Years - 75 Years | CStone Pharmaceuticals | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | NCT03421288 | Gastric Cancer Gastroesophagea... | Atezolizumab 5-Fluorouracil Calciumfolinat Oxaliplatin Docetaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | NCT05019794 | Gastric Cancer Gastroesophagea... Solid Tumor | Infigratinib | 18 Years - 75 Years | LianBio LLC | |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02539225 | Metastatic Gast... Gastroesophagea... | Ramucirumab Placebo S-1 Oxaliplatin Paclitaxel | 20 Years - | Eli Lilly and Company | |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer | NCT05111626 | Gastric Cancer Gastroesophagea... | Bemarituzumab Nivolumab Chemotherapy Placebo | 18 Years - 100 Years | Amgen | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | NCT04915807 | Gastric Cancer Gastroesophagea... | Ramucirumab and... Taxane, irinote... | 19 Years - | Hallym University Medical Center | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | NCT03966118 | Gastroesophagea... Adenocarcinoma ... | Avelumab Ramucirumab Paclitaxel | 18 Years - | Charite University, Berlin, Germany | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| A Study of KK2269 in Adult Participants With Solid Tumors | NCT06266299 | Advanced Solid ... Metastatic Soli... Gastric Adenoca... Gastroesophagea... Esophageal Aden... Non Small Cell ... | KK2269 Docetaxel | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | NCT00964080 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | MBP-426/Leucovo... | 18 Years - | Mebiopharm Co., Ltd | |
| Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | NCT02830594 | Gastric Adenoca... Gastric Squamou... Gastroesophagea... Metastatic Mali... Stage IV Esopha... Stage IV Esopha... | External Beam R... Laboratory Biom... Pembrolizumab | 18 Years - | City of Hope Medical Center | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 | Stomach Cancer Stomach Neoplas... Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | 70 Years - | Federation Francophone de Cancerologie Digestive | |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Esophageal cAncer Screening Trial | NCT04609813 | Esophageal Squa... Esophageal Canc... Gastroesophagea... | Sponge cytologi... | 40 Years - 75 Years | Changhai Hospital | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | NCT03511222 | Solid Tumor Hepatocellular ... Gastric Cancer Gastroesophagea... | Vorolanib Nivolumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | NCT05918419 | Gastroesophagea... | Serplulimab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | NCT05567835 | Gastric Adenoca... Gastroesophagea... | Fluorouracil Leucovorin Oxaliplatin Docetaxel GSCF | 18 Years - | Baylor College of Medicine | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | NCT05918419 | Gastroesophagea... | Serplulimab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | NCT04933227 | Stomach Neoplas... Gastric Cancer Gastroesophagea... | Atezolizumab Tiragolumab Oxaliplatin Capecitabine | 18 Years - | Hoffmann-La Roche | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | NCT02730546 | Gastric Cardia ... Gastroesophagea... Stage IB Gastri... Stage II Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... | Carboplatin Computed Tomogr... Fluorouracil Laboratory Biom... Leucovorin Calc... Oxaliplatin Paclitaxel Pembrolizumab Positron Emissi... Radiation Thera... Therapeutic Con... | 18 Years - 80 Years | Mayo Clinic | |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT04263870 | Gastroesophagea... Stomach Adenoca... Locally Advance... Metastatic Gast... | sintilimab | 18 Years - 75 Years | Sichuan University | |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | NCT02307812 | Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | - | Eli Lilly and Company | |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | NCT06324357 | Metastatic Brea... Metastatic Gast... Gastroesophagea... Esophageal Aden... | Zongertinib Trastuzumab der... Trastuzumab emt... | 18 Years - | Boehringer Ingelheim | |
| Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | NCT04018872 | Esophagus Adeno... Esophagus Squam... Gastroesophagea... | Itraconazole | 18 Years - | Dallas VA Medical Center | |
| Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | NCT03773367 | Resectable Gast... | Fluorouracil Oxaliplatin Irinotecan | 18 Years - | Lund University Hospital | |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | NCT03395847 | Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Gastroesophagea... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... | Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | NCT03592407 | Esophageal Squa... Esophageal Aden... Gastroesophagea... | Epacadostat Laboratory Biom... Pembrolizumab Pharmacodynamic... | 18 Years - | City of Hope Medical Center | |
| Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT01379807 | Gastric Adenoca... Gastroesophagea... | panitumumab + d... | 18 Years - | Grupo Gallego de Investigaciones Oncologicas | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | NCT05753306 | Gastric Adenoca... Gastroesophagea... Metastatic Mali... | Biospecimen Col... Cisplatin Computed Tomogr... Docetaxel Gastrectomy Hyperthermic In... Magnetic Resona... Positron Emissi... Questionnaire A... | 18 Years - 80 Years | Mayo Clinic | |
| A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | NCT03707028 | Gastric Cancer Gastroesophagea... | Rivoceranib Paclitaxel | 19 Years - | Elevar Therapeutics | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | NCT04805307 | Advanced Solid ... Gastric Cancer Gastroesophagea... Pancreatic Canc... | CMG901 | 18 Years - 75 Years | Keymed Biosciences Co.Ltd | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | NCT05393986 | Gastric Adenoca... Pancreatic Canc... Gastroesophagea... | CT048 Autologou... | 18 Years - 75 Years | Peking University | |
| Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT06155383 | Gastric Cancer Gastroesophagea... | Capecitabine oxaliplatin Disitamab Vedot... Toripalimab | 18 Years - | RemeGen Co., Ltd. | |
| Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction | NCT01962246 | Gastroesophagea... | Oxaliplatin; Ca... Oxaliplatin; Ca... | 18 Years - 75 Years | Hebei Medical University | |
| CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | NCT05207722 | Metastatic HER2... | CYNK-101 Pembrolizumab Trastuzumab Recombinant Hum... Cyclophosphamid... Fludarabine Mesna | 18 Years - 75 Years | Celularity Incorporated | |
| Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT06155383 | Gastric Cancer Gastroesophagea... | Capecitabine oxaliplatin Disitamab Vedot... Toripalimab | 18 Years - | RemeGen Co., Ltd. | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | NCT03511222 | Solid Tumor Hepatocellular ... Gastric Cancer Gastroesophagea... | Vorolanib Nivolumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | NCT04683939 | Solid Tumor Gastric Cancer Gastroesophagea... Esophageal Aden... Pancreatic Canc... Biliary Tract C... Cholangiocarcin... Metastatic Canc... | BNT141 Nab-paclitaxel Gemcitabine | 18 Years - | BioNTech SE | |
| Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma | NCT06353152 | Gastric Adenoca... Gastroesophagea... | Claudin18.2-Tar... | 18 Years - 70 Years | Peking University | |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | NCT04510285 | Esophagogastric... Gastric Cancer Gastric Tumor Esophageal Canc... Esophageal Neop... Esophageal Tumo... GastroEsophagea... Gastroesophagea... Gastroesophagea... Gastroesophagea... | Trastuzumab Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer | NCT02891447 | Gastric Adenoca... Gastroesophagea... Peritoneal Carc... | Cisplatin Hyperthermic In... Mitomycin | 18 Years - | M.D. Anderson Cancer Center | |
| Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | NCT05753306 | Gastric Adenoca... Gastroesophagea... Metastatic Mali... | Biospecimen Col... Cisplatin Computed Tomogr... Docetaxel Gastrectomy Hyperthermic In... Magnetic Resona... Positron Emissi... Questionnaire A... | 18 Years - 80 Years | Mayo Clinic | |
| Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma | NCT02193594 | Gastroesophagea... | Preoperative co... Radical D2 tota... Adjuvant chemot... | 18 Years - 80 Years | Peking University | |
| A Multicenter Cancer Biospecimen Collection Study | NCT04510129 | Cancer of Head ... Lung Cancer, No... Small-cell Lung... Urothelial Carc... Gastroesophagea... Cervical Cancer Esophageal Squa... Triple Negative... Hepatocellular ... Renal Cell Carc... Colorectal Canc... | OncoPrism™ assa... | 18 Years - | Cofactor Genomics, Inc. | |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | NCT06265285 | Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc... | Home Health Enc... Nivolumab Patient Monitor... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | NCT00515411 | Gastroesophagea... Gastric Cancer | Docetaxel, Leuc... Docetaxel, Cisp... Docetaxel, Leuk... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PEN-866 in Patients With Advanced Solid Malignancies | NCT03221400 | Carcinoma Endometrial Ade... Neoplasms Squamous Cell C... Adenocarcinoma ... Advanced Cancer Solid Tumor Solid Carcinoma Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Gastric Cancer Gastric Adenoca... Gastroesophagea... Small-cell Lung... Small Cell Lung... Pancreatic Duct... Pancreatic Aden... | PEN-866 Sodium fluorouracil Folinic acid Niraparib | 18 Years - | Tarveda Therapeutics | |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | NCT02128243 | Unresectable, L... Gastric Neoplas... Gastroesophagea... Esophageal Aden... Gastric Adenoca... Esophageal Neop... | S-1 de-escalati... Chemotherapy by... | 18 Years - | AIO-Studien-gGmbH | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | NCT02370498 | Gastric Adenoca... Gastroesophagea... | pembrolizumab paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05111444 | Gastric Neoplas... Gastroesophagea... | Camrelizumab Pyrotinib Capecitabine Oxaliplatin Paclitaxel S-1 | 18 Years - 75 Years | Fudan University | |
| Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery | NCT05203627 | Gastric Carcino... Gastroesophagea... | Best Practice Questionnaire A... Telemedicine Vi... | 21 Years - | City of Hope Medical Center | |
| Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | NCT05393986 | Gastric Adenoca... Pancreatic Canc... Gastroesophagea... | CT048 Autologou... | 18 Years - 75 Years | Peking University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
